NCT05996484View on ClinicalTrials.gov

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

July 31, 2026

Conditions
Esophageal CarcinomaNeoadjuvant Therapy
Interventions
DRUG

Toripalimab

Toripalimab, 240mg, IV., D1, every 3 weeks, 4 cycles.

DRUG

Anlotinib hydrochloride

Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off, every 3 weeks, 4 cycles.

DRUG

Albumin paclitaxel

Albumin paclitaxel, 200-260 mg/m2, IV., D1, every 3 weeks, 4 cycles.

DRUG

Cisplatin

Cisplatin, 60-75 mg/m2, IV., D1, every 3 weeks, 4 cycles.

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT05996484 - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma | Biotech Hunter | Biotech Hunter